Poseida Therapeutics, Inc. Proceeds from Issuance Initial Public Offering
Poseida Therapeutics, Inc. reported Proceeds from Issuance Initial Public Offering of $205.74 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2022-03-10
- Poseida Therapeutics, Inc. proceeds from issuance initial public offering for the quarter ending 2020-12-31 was $0.00.
- Poseida Therapeutics, Inc. proceeds from issuance initial public offering for fiscal 2020 was $205.74M.
| Period end | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 9 month | Proceeds from Issuance Initial Public Offering 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $205.74M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $205.74M 10-Q · filed 2021-11-09 |